News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Lytix Biopharma Announces Regulatory Approval by Swedish Authorities to Commence Phase I/IIa Clinical Trial with LytixarTM (LTX-109) in MRSA


5/24/2010 10:47:24 AM

TROMSØ & OSLO, Norway--(BUSINESS WIRE)--The Norwegian pharmaceutical company Lytix Biopharma AS today announces the approval by the Swedish Medical Products Agency (”Läkemedelverket”) to commence a Phase I/IIa clinical trial with LytixarTM (LTX-109) for nasal decolonisation of MRSA (methicillin-resistant Staphylococcus aureus).

Read at BioSpace.com

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES